Nearly two years after its creation, the complex generic drug parallel scientific advice pilot program still has not received enough interest to effectively judge its value.
Key Takeaways
-
The FDA wants to drum up more interest in the parallel scientific advice program for complex generics after only two requests have been received.
US Food and Drug Administration officials are trying to drum up more interest in the program, which allows complex generics...